Company: APXIF
Filing Date: 2025-06-11
Form Type: 10-Q
Source: 0001213900-25-053185
Chunk: 51

Company: APx Acquisition Corp. I
Filing Date: 2025-06-11
Form: 10-Q
Item: Part I, Item 1
Chunk 51
---
 ruling (whether temporary, preliminary or permanent) which has become final and non-appealable and has the
effect of making consummation of the Transactions illegal or otherwise preventing or prohibiting consummation of the Transaction or the
Merger; (iv) by OmnigenicsAI if the SPAC Shareholders’ Approval shall not have been obtained by reason of the failure to obtain
the required vote at the SPAC Shareholders’ Meeting duly convened therefor or at any adjournment thereof; (v) by the Company
upon a breach of any representation, warranty, covenant or agreement set forth in the Business Combination Agreement on the part of OmnigenicsAI
or Merger Sub, subject to certain exceptions and cure periods set forth in the Business Combination Agreement, such that the conditions
relating to representations and warranties and certain covenants and agreements would not be satisfied; (vi) by OmnigenicsAI upon
any breach of any representation, warranty, covenant or agreement set forth in the Business Combination Agreement on the part of the Company,
subject to certain exceptions and cure periods set forth in the Business Combination Agreement, such that the conditions relating to representations
and warranties and certain covenants and agreements would not be satisfied; (vii) by the Company in the event (A) (1) MultiplAI
or any of the MultiplAI Shareholders breaches or violates any representation, warranty, covenant, agreement or obligation contained in
the MultiplAI SPA, subject to certain exceptions and cure periods set forth in the Business Combination Agreement, such that the conditions
relating to representations and warranties and certain covenants and agreements contained in the MultiplAI SPA would not be satisfied,
(2) of a MultiplAI Material Adverse Effect, or (3) of a breach of any representation, warranty, covenant or agreement set forth
in the Business Combination Agreement on the part of MultiplAI, subject to certain exceptions and cure periods set forth in the Business
Combination Agreement, such that the conditions relating to representations and warranties and certain covenants and agreements would
not be satisfied, and (B) the Company exercises its right to cause the Parent to terminate the MultiplAI SPA and the MultiplAI SPA
is not terminated following the expiration of certain cure periods; and (viii) by the Company if the SEC Required Financials shall
not have been delivered by OmnigenicsAI or MultiplAI, on